- Certara, Inc. is a global leader in model-informed drug development, specializing in AI-enabled biosimulation technologies that enhance drug development processes.
- In 2026, Certara reported FY 2025 revenue of $418.8 million, a 9% growth, and appointed Jon Resnick as CEO, who aims to transform operational strategies and achieve $10 million in cost avoidance.
- The company recently expanded its Simcyp Simulator, the first EMA-qualified PBPK platform, to streamline regulatory submissions and enhance drug development efficiency.
- Certara's ideal buyers are pharmaceutical and biotechnology companies looking to optimize drug development and regulatory processes, addressing the critical need for credible, model-informed evidence in submissions.
Engineering is the largest group at 140 employees, about 26% of the company. Marketing and Product (89; ~16%) and Business Management (87; ~16%) form substantial portions of the organization, followed by Sales and Support (76; ~14%). Additional functions include Finance and Administration (35), Operations (27), Information Technology (18), Healthcare (15), Human Resources (15), and Other (47), indicating a balanced mix of technical, go-to-market, and corporate teams.
Certara’s workforce is broadly distributed, with 379 employees categorized under Other locations (~69%), indicating a wide multi-site or remote footprint. Notable hubs include Philadelphia, PA (51; ~9%), Raleigh, NC (30; ~6%), New York, NY (20; ~4%), and Boston, MA (18; ~3%). Additional teams are present in Princeton, NJ; Seattle, WA; St. Louis, MO; as well as international locations such as Montreal, Canada and Sheffield, UK, each with around 10 employees.
